Patents Assigned to Norgine BV
  • Patent number: 10016504
    Abstract: The invention provides a colon cleansing solution comprising: a) 300 to 800 mmol per liter ascorbate anion provided by a mixture of: (i) ascorbic acid and (ii) one or more salts of ascorbic acid the components (i) and (ii) being present in a molar ratio of from 1:4.5 to 1:7.0; and b) 10 to 200 g per liter polyethylene glycol. The invention also provides methods and kits associated with, or making use of the solutions, and compositions for the preparation of the solutions.
    Type: Grant
    Filed: March 9, 2017
    Date of Patent: July 10, 2018
    Assignee: NORGINE BV
    Inventors: Lucy Clayton, Alasdair Cockett, Mark Christodoulou, Ian Davidson, Lynn Farrag, Marc Halphen, Leighton Jones, Vanik Petrossian, Peter Stein, David Tisi, Alex Ungar, Jeffrey Worthington
  • Patent number: 9707297
    Abstract: The invention provides a colon cleansing solution comprising: a) 300 to 800 mmol per liter ascorbate anion provided by a mixture of: (i) ascorbic acid and (ii) one or more salts of ascorbic acid the components (i) and (ii) being present in a molar ratio of from 1:4.5 to 1:7.0; and b) 10 to 200 g per liter polyethylene glycol. The invention also provides methods and kits associated with, or making use of the solutions, and compositions for the preparation of the solutions.
    Type: Grant
    Filed: April 28, 2016
    Date of Patent: July 18, 2017
    Assignee: NORGINE BV
    Inventors: Lucy Clayton, Alasdair Cockett, Mark Christodoulou, Ian Davidson, Lynn Farrag, Marc Halphen, Leighton Jones, Vanik Petrossian, Peter Stein, David Tisi, Alex Ungar, Jeffrey Worthington
  • Publication number: 20170119816
    Abstract: The invention provides a colon cleansing solution comprising: a) 300 to 2000 mmol per litre ascorbate anion provided by ascorbic acid, one or more salts of ascorbic acid, or a mixture thereof; and b) 10 to 200 g per litre polyethylene glycol. The invention also provides methods and kits associated with, or making use of the solutions. The invention also provides a method of cleansing the colon of a subject comprising: —administering to the subject an effect amount of a first cleansing solution; and then after a time interval —administering to the subject an effective amount of a second cleansing solution, wherein the two cleansing solutions are as described in the specification.
    Type: Application
    Filed: January 16, 2017
    Publication date: May 4, 2017
    Applicant: NORGINE BV
    Inventors: Marc Halphen, Hans-Jurgen GRUSS, Ian Cox, Alasdair Cockett, Peter Stein, Alex Ungar
  • Patent number: 9592252
    Abstract: The invention provides a colon cleansing solution comprising: a) 300 to 2000 mmol per liter ascorbate anion provided by ascorbic acid, one or more salts of ascorbic acid, or a mixture thereof; and b) 10 to 200 g per liter polyethylene glycol. The invention also provides methods and kits associated with, or making use of the solutions. The invention also provides a method of cleansing the colon of a subject comprising: —administering to the subject an effective amount of a first cleansing solution; and then after a time interval —administering to the subject an effective amount of a second cleansing solution, where in the two cleansing solutions are as described in the specification.
    Type: Grant
    Filed: March 9, 2012
    Date of Patent: March 14, 2017
    Assignee: NORGINE BV
    Inventors: Marc Halphen, Hans-Jurgen Gruss, Ian Cox, Alasdair Cockett, Peter Stein, Alex Ungar
  • Patent number: 9468686
    Abstract: A solution in water comprising the following components at the following concentrations: (a) N×(70 to 130) g/L polyethylene glycol (PEG) having an average molecular weight of 2500 to 4500; (b) N×(1.6 to 4.0) g/L sodium chloride; (c) N×(0.2 to 0.6) g/L potassium chloride; (d) N×(0.6 to 2.2) g/L sodium bicarbonate; (e) N×an amount of preservative; (f) optionally N x an amount of flavouring; and (g) optionally N×an amount of sweetener, where N is in the range of 2 to 8. The solution is a concentrate for dilution. In use it is diluted N-fold with water to provide a solution for administration to a subject for the treatment of constipation or faecal impaction. Also provided are solutions, kits, unit doses and methods that comprise or use the solutions.
    Type: Grant
    Filed: January 28, 2014
    Date of Patent: October 18, 2016
    Assignee: NORGINE BV
    Inventors: Chris Seldon, Dawn Padfield, Frances Morrissey
  • Patent number: 9326969
    Abstract: The invention provides a colon cleansing solution comprising: a) 300 to 800 mmol per litre ascorbate anion provided by a mixture of: (i) ascorbic acid and (ii) one or more salts of ascorbic acid the components (i) and (ii) being present in a molar ratio of from 1:4.5 to 1:7.0; and b) 10 to 200 g per litre polyethylene glycol. The invention also provides methods and kits associated with, or making use of the solutions, and compositions for the preparation of the solutions.
    Type: Grant
    Filed: March 13, 2015
    Date of Patent: May 3, 2016
    Assignee: NORGINE BV
    Inventors: Lucy Clayton, Alasdair Cockett, Mark Christodoulou, Ian Davidson, Lynn Farrag, Marc Halphen, Leighton Jones, Vanik Petrossian, Peter Stein, David Tisi, Alex Ungar, Jeffrey Worthington
  • Patent number: 8999313
    Abstract: The invention provides a colon cleansing solution comprising: a) 300 to 800 mmol per liter ascorbate anion provided by a mixture of: (i) ascorbic acid and (ii) one or more salts of ascorbic acid the components (i) and (ii) being present in a molar ratio of from 1:4.5 to 1:7.0; and b) 10 to 200 g per liter polyethylene glycol. The invention also provides methods an kits associated with, or making use of the solutions, and compositions for the preparation of the solutions.
    Type: Grant
    Filed: March 24, 2014
    Date of Patent: April 7, 2015
    Assignee: Norgine BV
    Inventors: Lucy Clayton, Alasdair Cockett, Mark Christodoulou, Ian Davidson, Lynn Farrag, Marc Halphen, Leighton Jones, Vanik Petrossian, Peter Stein, David Tisi, Alex Ungar, Jeffrey Worthington
  • Publication number: 20140178477
    Abstract: The present invention provides a solid preparation formulation containing a poorly water-soluble agent having a low melting point, a saccharide, and a cellulose selected from a crystalline cellulose and a low-substituted hydroxypropylcellulose, in which the saccharide/cellulose weight ratio exceeds 2 and the cellulose content is not less than 5 wt %. This formulation provides a composition that can be produced with direct granulation, yet which delivers stability during production and storage.
    Type: Application
    Filed: February 26, 2014
    Publication date: June 26, 2014
    Applicant: Norgine BV
    Inventors: Tomohiro Yoshinari, Yutaka Ebisawa, Hiroshi Suzuki
  • Publication number: 20140147518
    Abstract: The invention provides a solution in water comprising the following components at the following concentrations: (a) N×(70 to 130) g/L polyethylene glycol (PEG) having an average molecular weight of 2500 to 4500; (b) N×(1.6 to 4.0) g/L sodium chloride; (c) N×(0.2 to 0.6) g/L potassium chloride; (d) N×(0.6 to 2.2) g/L sodium bicarbonate; (e) N×an amount of preservative; (f) optionally N×an amount of flavouring; and (g) optionally N×an amount of sweetener where N is in the range of 2 to 8. The solution is a concentrate for dilution. In use it is diluted N-fold with water to provide a solution for administration to a subject for the treatment of constipation or faecal impaction. Also provided are solutions, kits, unit doses and methods that comprise or use the solutions.
    Type: Application
    Filed: January 28, 2014
    Publication date: May 29, 2014
    Applicant: NORGINE BV
    Inventors: Chris Seldon, Dawn Padfield, Frances Morrissey
  • Publication number: 20140010895
    Abstract: The invention provides a colon cleansing solution comprising: a) 300 to 2000 mmol per litre ascorbate anion provided by ascorbic acid, one or more salts of ascorbic acid, or a mixture thereof; and b) 10 to 200 g per litre polyethylene glycol. The invention also provides methods and kits associated with, or making use of the solutions. The invention also provides a method of cleansing the colon of a subject comprising: — administering to the subject an effective amount of a first cleansing solution; and then after a time interval-administering to the subject an effective amount of a second cleansing solution, where in the two cleansing solutions are as described in the specification.
    Type: Application
    Filed: March 9, 2012
    Publication date: January 9, 2014
    Applicant: NORGINE BV
    Inventors: Marc Halphen, Hans-Jurgen Gruss, Ian Cox, Alasdair Cockett, Peter Stein, Alex Ungar
  • Patent number: 8613948
    Abstract: 1R,2S-Methoxamine may be used topically for effective treatment of faecal incontinence at low doses without local or systemic side effects, for example, without affecting blood pressure. 1R,2S-Methoxamine may be used to treat other disturbances and disorders of the gastro-intestinal, as a pressor agent, as a nasal decongestant and in ophthalmology, at low does and without significant side effects.
    Type: Grant
    Filed: November 15, 2012
    Date of Patent: December 24, 2013
    Assignee: Norgine BV
    Inventors: Norman Barras, Jeffrey Martin Thompson
  • Publication number: 20130216493
    Abstract: The present invention relates to methods for and of treating, ameliorating or preventing colorectal cancer (CRC) in humans using polyethylene glycol (PEG) or a PEG block-copolymer such as Pluronic® F68. Compositions for use in treating, ameliorating and/or preventing CRC comprising PEG are also disclosed. Such compositions may be used in the methods of the invention.
    Type: Application
    Filed: November 4, 2011
    Publication date: August 22, 2013
    Applicant: Norgine BV
    Inventors: Peter Stein, Leighton Jones, Samuel Smith, Ian Cox, Jörg Plessl, Corinne De Vries, Rachel Charlton
  • Patent number: 8513023
    Abstract: A method of determining the functional activity of the MRP2 and/or MRP3 efflux pathway of a human or animal subject was disclosed. The method comprises (i) determining the level of a bile acid derivative in the blood of said human or animal subject at a predetermined time interval after introducing an amount of the bile acid derivative into the subject, and (ii) using the determination obtained in step (i) to indicate the functional activity of the MRP2 and/or MRP3 efflux pathway of the subject.
    Type: Grant
    Filed: October 25, 2012
    Date of Patent: August 20, 2013
    Assignee: Norgine BV
    Inventors: Hans-Jürgen Gruss, Ronald Oude Elferink, Dirk De Waart, Bruno Stieger
  • Publication number: 20130189377
    Abstract: The present invention concerns solid compressed oral pharmaceutical compositions comprising a mixture of at least two sulphate salts selected from the group consisting of sodium, potassium and magnesium for use, in particular, in cleansing the colon or treating faecal impaction, constipation, faecal retention, intestinal gas and cramping, or flatulence in a mammal. Methods of producing such compositions are also disclosed.
    Type: Application
    Filed: July 26, 2011
    Publication date: July 25, 2013
    Applicant: Norgine BV
    Inventors: Alasdair Cockett, Paul Pay, Guy Cameron Nash
  • Patent number: 8491931
    Abstract: 1R,2S-Methoxamine may be used topically for effective treatment of faecal incontinence at low doses without local or systemic side effects, for example, without affecting blood pressure. 1R,2S-Methoxamine may be used to treat other disturbances and disorders of the gastrointestinal, as a pressor agent, as a nasal decongestant and in ophthalmology, at low does and without significant side effects.
    Type: Grant
    Filed: September 30, 2009
    Date of Patent: July 23, 2013
    Assignee: Norgine BV
    Inventors: Norman Barras, Jeffrey Martin Thompson
  • Publication number: 20130072567
    Abstract: 1R,2S-Methoxamine may be used topically for effective treatment of faecal incontinence at low doses without local or systemic side effects, for example, without affecting blood pressure. 1R,2S-Methoxamine may be used to treat other disturbances and disorders of the gastro-intestinal, as a pressor agent, as a nasal decongestant and in ophthalmology, at low does and without significant side effects.
    Type: Application
    Filed: November 15, 2012
    Publication date: March 21, 2013
    Applicant: NORGINE BV
    Inventor: Norgine BV
  • Publication number: 20130042671
    Abstract: A method of determining the functional activity of the MRP2 and/or MRP3 efflux pathway of a human or animal subject was disclosed. The method comprises (i) determining the level of a bile acid derivative in the blood of said human or animal subject at a predetermined time interval after introducing an amount of the bile acid derivative into the subject, and (ii) using the determination obtained in step (i) to indicate the functional activity of the MRP2 and/or MRP3 efflux pathway of the subject.
    Type: Application
    Filed: October 25, 2012
    Publication date: February 21, 2013
    Applicant: NORGINE BV
    Inventor: NORGINE BV
  • Patent number: 8318504
    Abstract: In one aspect a method of determining the functional activity of the MRP2 and/or MRP3 efflux pathway of a human or animal subject, comprises: (i) determining the level of a bile acid derivative in the blood of said human or animal subject at a predetermined time interval after introducing an amount of the bile acid derivative into the subject; and (ii) using the determination obtained in step (i) to indicate the functional activity of the MRP2 and/or MRP3 efflux pathway of the subject.
    Type: Grant
    Filed: May 14, 2009
    Date of Patent: November 27, 2012
    Assignee: Norgine BV
    Inventors: Hans-Jürgen Gruss, Ronald Oude Elferink, Dirk de Waart, Bruno Stieger
  • Publication number: 20100297263
    Abstract: A composition comprising, per litre of aqueous solution, from 30 to 350 g polyethylene glycol, from 3 to 20 g of an ascorbic acid component selected form the group consisting of ascorbic acid, a salt of ascorbic acid, or a mixture thereof, an alkali metal or alkaline earth metal sulphate, preferably from 1 to 15 g thereof, and optionally one or more electrolytes selected from sodium chloride, potassium chloride, and sodium hydrogen carbonate, and preferably also comprising flavourings, is effective in cleansing the gut in preparation for a endoscopy, especially colonoscopy. It is safer than conventional sodium phosphate-based gut cleansing compositions, and hence can be used for patients who would be at risk with sodium phosphate-based compositions, and is better tolerated than conventional PEG-based compositions, leading to better patient compliance and enabling effective out-patient use.
    Type: Application
    Filed: August 7, 2010
    Publication date: November 25, 2010
    Applicant: NORGINE BV
    Inventors: Norman Barras, Ian David Cox, Alex Ungar, Marc Halphen
  • Publication number: 20100196513
    Abstract: A composition comprising, per litre of aqueous solution, from 30 to 350 g polyethylene glycol, from 3 to 20 g of an ascorbic acid component selected form the group consisting of ascorbic acid, a salt of ascorbic acid, or a mixture thereof, an alkali metal or alkaline earth metal sulphate, preferably from 1 to 15 g thereof, and optionally one or more electrolytes selected from sodium chloride, potassium chloride, and sodium hydrogen carbonate, and preferably also comprising flavourings, is effective in cleansing the gut in preparation for a endoscopy, especially colonoscopy. It is safer than conventional sodium phosphate-based gut cleansing compositions, and hence can be used for patients who would be at risk with sodium phosphate-based compositions, and is better tolerated than conventional PEG-based compositions, leading to better patient compliance and enabling effective out-patient use.
    Type: Application
    Filed: April 5, 2010
    Publication date: August 5, 2010
    Applicant: NORGINE BV
    Inventors: Norman Barras, Ian David Cox, Alex Ungar, Marc Halphen